No­var­tis plans BTK in­hibitor fil­ing in chron­ic spon­ta­neous ur­ticaria as Celldex’s mid-stage da­ta ex­cite in­vestors

No­var­tis un­veiled pos­i­tive reg­is­tra­tional da­ta for its BTK in­hibitor can­di­date in chron­ic spon­ta­neous ur­ticaria, trig­ger­ing plans for reg­u­la­to­ry fil­ings.

But strong Phase II read­out from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER